ライフサイエンスコーパス: non-inferior

1 nsidering a difference of less than 6% to be non-inferior.

2 weeks of oral flucanozole (FLU) plus 5FC was non-inferior.

3 riority)=0.0005) and the hybrid approach was non-inferior (282 [68%] vs 269 [63%], RR 1.08, 0.98-1.19

4 sis that using rituximab would be clinically non-inferior and cheaper compared with TNF inhibitor tre

5 -bearing strategy was found to be clinically non-inferior and highly likely to be cost-effective comp

6 t with 8 Gy in a single fraction seems to be non-inferior and less toxic than 20 Gy in multiple fract

7 .9% vs. 26.1%) that resulted in a shock were non-inferior and lower in the EMPIRIC arm compared to th

8 4F-PCC is non-inferior and superior to plasma for rapid INR revers

9 Aflibercept was non-inferior and superior to PRP in both the modified in

10 Zoledronic acid was non-inferior and superior to risedronate for increase of

11 hort schedules for mOPV1 and bOPV elicited a non-inferior antibody response compared with the bOPV st

12 o-dose primary series of PCV13 (group E) was non-inferior at the 10% level to a three-dose primary se

13 I system showed a statistically superior and non-inferior AUROC of 0.91 (95% CI 0.87-0.94; p<0.0001),

14 Aflibercept 8q12 and 8q16 demonstrated non-inferior BCVA gains to aflibercept 2q8 (BCVA mean ch

15 Aflibercept 8q12 and 8q16 showed non-inferior BCVA gains versus aflibercept 2q8 (mean BCV

16 8.4 to 1.5), indicating that raltegravir was non-inferior, but not superior, to NRTIs.

17 ix-PT and that this would lead to at least a non-inferior clinical outcome compared with monitoring w

18 ost diagnosis, less frequent mammograms were non-inferior compared with annual mammograms for breast

19 Bivalent OPV was non-inferior compared with monovalent OPV (p=0.21).

20 A once daily raltegravir 1200 mg regimen was non-inferior compared with raltegravir 400 mg twice dail

21 Eosinophil-guided therapy was non-inferior compared with standard care for the number

22 er APBI using multicatheter brachytherapy is non-inferior compared with whole-breast irradiation.

23 stuzumab for subcutaneous injection provides non-inferior cycle 7 pertuzumab serum C(trough) concentr

24 n this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of

25 In this study, we show that CT-P10 exhibits non-inferior efficacy and pharmacokinetic equivalence to

26 INTERPRETATION: The non-inferior efficacy and similar safety profile of the

27 The non-inferior efficacy and similar tolerability profile o

28 al failures, a favourable safety profile and non-inferior efficacy compared with efavirenz means that

29 avir and rilpivirine dosed every 8 weeks had non-inferior efficacy compared with that of every 4 week

30 fined by treatment-related morbidity and (2) non-inferior efficacy defined by progression-free surviv

31 ine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bo

32 mtricitabine and tenofovir alafenamide shows non-inferior efficacy to daily emtricitabine and tenofov

33 tment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was

34 verse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, wi

35 and raltegravir (raltegravir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and

36 -acting cabotegravir plus rilpivirine showed non-inferior efficacy versus bictegravir, emtricitabine,

37 rapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and

38 LSTENT plus FilterWire embolic protection is non-inferior (equivalent or better than) to CEA at 1-yea

39 containing tenofovir disoproxil fumarate was non-inferior for maintenance of viral suppression and le

40 Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embol

41 At 9 months of age, the 6 + 10 schedule was non-inferior for serotype 5 (79 [55.2%] of 143 vs 78 [53

42 single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month ap

43 iration as first pass thrombectomy conferred non-inferior functional outcome at 90 days compared with

44 s treated with aspiration as first pass have non-inferior functional outcomes to those treated with a

45 ive validations, the model shows superior or non-inferior genetic matching and neutralization against

46 type 1 diabetes, once-weekly efsitora showed non-inferior HbA(1c) reduction compared with daily insul

47 Efsitora showed non-inferior HbA(1c) reductions and similar rates of com

48 e related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses wh

49 Treatment with OSC alone was considered non-inferior if it was no more than 7 QALY days worse th

50 her immune responses to PCV10 serotypes were non-inferior if the second priming dose of PCV10 was del

51 On-demand treatment was considered non-inferior if the upper limit of the one-sided 95 % co

52 iation dose across paediatric patients, with non-inferior image quality.

53 Fractional vaccine doses generated non-inferior immune responses compared to standard doses

54 three-dose prime-only PCV schedule provided non-inferior immunogenicity in early infancy and superio

55 ique for applying alcohol-based hand rub was non inferior in terms of reduction of bacterial counts,

56 abine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppression and was we

57 ther efficacy, safety, and tolerability were non-inferior in patients switched to a regimen containin

58 ates against polioviruses types 1 and 3 were non-inferior in sequential schedules containing IPV and

59 We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in

60 diation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as

61 itabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would im

62 HPV 6, 11, 16, and 18 GMTs were non-inferior in the 9vHPV versus qHPV group from month 1

63 ater than -10%) at 28 days after dose 2 were non-inferior in the AZD2816 (4-week) group against beta

64 The time to first all-cause shock was non-inferior in the EMPIRIC arm (hazard ratio = 0.95, 90

65 vs 10.3, 0.78 [0.64-0.96], p=0.0086) and was non-inferior in the total population (11.6 vs 10.7, 0.85

66 O of 3-weeks gave similar (and statistically non-inferior) incidences of remission and AE to a course

67 dpoints of superior vasomotor reactivity and non-inferior late luminal loss for the Absorb bioresorba

68 Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1.63

69 For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean differenc

70 -case assumptions (80% vaccination coverage, non-inferior one-dose vaccine, and unfeasibility of incr

71 included in the international, multicenter, non-inferior, open label, randomized, controlled trials

72 Antibodies and T cell immune responses are non-inferior or similar in adolescents receiving 2 doses

73 are needed to conclude that PEARS could be a non-inferior or superior alternative to conventional aor

74 an adjunct to anti-VEGF therapy demonstrated non-inferior outcomes in central retinal thickness (p =

75 the reader study, AI achieved statistically non-inferior (p<0.0001) and superior (p=0.001) performan

76 UK, and found that the AI system maintained non-inferior performance and reduced the workload of the

77 n a human reader study, the AI system showed non-inferior performance to conventional assessment and

78 LoRa-finetuned Llama-3.1 8B achieved non-inferior performance to the second human annotator a

79 r severe aortic regurgitation, TAVR was both non-inferior (pooled weighted proportion difference of -

80 g intravenous infusion of zoledronic acid is non-inferior, possibly more effective, and more acceptab

81 LAVASET yields mostly non-inferior prediction accuracies to traditional RFs wh

82 emic antibiotic treatment is associated with non-inferior results for clinical remission and adverse

83 ned treatment of non-contained IBDs produces non-inferior results in terms of CAL gain, PPD reduction

84 that the advanced practice nursing model was non-inferior (risk ratio: 0.45, 95% CI: 0.21-0.97).

85 A non-inferior set estimation (MONISE) algorithm for ident

86 Early BC patients treated with APBI showed non-inferior short-term and late HRQoL outcomes compared

87 comparable sensitivity in later disease and non-inferior specificity.

88 INTEREST established non-inferior survival of gefitinib compared with docetax

89 However, it has not been shown to be non inferior to current implantable cardioverter-defibri

90 clusively, a stepwise DAPT de-escalation was non-inferior to 12 month DAPT for net adverse clinical e

91 shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2

92 terisation after repair of simple fistula is non-inferior to 14 day catheterisation and could be used

93 sh whether 7 day bladder catheterisation was non-inferior to 14 days in terms of incidence of fistula

94 6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine.

95 Rate of seroconversion in 3AV (100%) was non-inferior to 1AV (97.9%) at Study Day 210 [Difference

96 Time to local progression with 4 Gy was not non-inferior to 24 Gy (hazard ratio 3.42, 95% CI 2.09-5.

97 controlled HIV, 2 doses of HPV 9v-vaccine is non-inferior to 3 doses in terms of seroconversion and i

98 ionated schedule of 55 Gy in 20 fractions is non-inferior to 64 Gy in 32 fractions with regard to bot

99 60 Gy was non-inferior to 74 Gy (HR 0.84 [90% CI 0.68-1.03], pNI=0

100 rifampicin, pyrazinamide, and ethambutol) is non-inferior to a 6-month regimen.

101 emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir-containing regimen in tre

102 fficacy of simplified three-dose regimens is non-inferior to a five-dose regimen.

103 n intensification provides glycaemic control non-inferior to a full basal-bolus regimen after 32 week

104 that a single dose of gentamicin 240 mg was non-inferior to a single dose of ceftriaxone 500 mg for

105 nib and methotrexate combination therapy was non-inferior to adalimumab and methotrexate combination

106 BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mea

107 nts [1.72 events per 100 patient-years]) was non-inferior to allopurinol (241 patients [2.05 events p

108 Febuxostat is non-inferior to allopurinol therapy with respect to the

109 Dolutegravir has been shown to be non-inferior to an integrase inhibitor and superior to a

110 mastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to convention

111 ethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose de

112 09, thus cisplatin plus gemcitabine was both non-inferior to and superior to paclitaxel plus gemcitab

113 by the perception that alternatives must be non-inferior to approved regimens.

114 o-severe ischaemic stroke, indobufen was not non-inferior to aspirin because the upper limit of the 9

115 nction, initial assessment of LVEF by AI was non-inferior to assessment by sonographers.

116 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome

117 boosted lopinavir plus raltegravir would be non-inferior to boosted lopinavir plus NRTIs for virolog

118 emtricitabine, and tenofovir alafenamide was non-inferior to both dolutegravir-containing regimens fo

119 erior to SABA in ensuring asthma control and non-inferior to budesonide maintenance therapy in preven

120 Treosulfan was non-inferior to busulfan when used in combination with f

121 OBLE trial aimed to evaluate whether PCI was non-inferior to CABG in the treatment of left main coron

122 study, DTG + FTC as maintenance therapy was non-inferior to cART in terms of efficacy, with a simila

123 DTG + FTC was non-inferior to cART.

124 Our data show that rezafungin was non-inferior to caspofungin for the primary endpoints of

125 BA was non-inferior to CBT (mITT: CBT 8.4 PHQ-9 points [SD 7.5]

126 At this point, tai chi was considered non-inferior to CBT-I because the upper confidence limit

127 Gepotidacin was non-inferior to ceftriaxone plus azithromycin.

128 nalysis of overall survival, panitumumab was non-inferior to cetuximab (Z score -3.19; p=0.0007).

129 Our findings show that panitumumab is non-inferior to cetuximab and that these agents provide

130 n 92% of previously untreated adults and was non-inferior to coformulated dolutegravir, abacavir, and

131 syndrome, treatment with the bioadaptor was non-inferior to contemporary DES, showing potential to m

132 regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four

133 emtricitabine, and tenofovir alafenamide was non-inferior to continuing rilpivirine, emtricitabine, t

134 demand treatment with esomeprazole 20 mg was non-inferior to continuous maintenance treatment and red

135 Direct oral anticoagulants are non-inferior to conventional anticoagulants for the trea

136 radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy i

137 erate hypofractionation has been shown to be non-inferior to conventional fractionation.

138 Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azath

139 long-acting cabotegravir and rilpivirine is non-inferior to daily dolutegravir, abacavir, and lamivu

140 oviral therapy (LA ART) has been found to be non-inferior to daily oral ART in phase 3 clinical trial

141 intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention an

142 laxis (PrEP) agents by showing that they are non-inferior to daily oral tenofovir disoproxil fumarate

143 suppression during 96 weeks; dolutegravir is non-inferior to darunavir but is at greater risk of resi

144 sehold members with prior year SSTI would be non-inferior to decolonizing all household members.

145 Immediate PrEP was non-inferior to deferred PrEP if the upper bound of the

146 ent in bony defects in the esthetic zone was non-inferior to delayed implant placement after 1 year.

147 lacement with delayed provisionalization was non-inferior to delayed implant placement with delayed p

148 roke associated with atrial fibrillation was non-inferior to delayed initiation for the composite out

149 emtricitabine, and tenofovir alafenamide was non-inferior to dolutegravir, abacavir, and lamivudine,

150 us rilpivirine long-acting every 8 weeks was non-inferior to dosing every 4 weeks (HIV-1 RNA >=50 cop

151 us rilpivirine long-acting every 8 weeks was non-inferior to dosing every 4 weeks (HIV-1 RNA 50 copie

152 irmed 95.6% versus 92.7% (p = 0.31); WOT was non-inferior to DOT (difference 2.8% CI [-1.8%, 9.1%]).

153 n order to test the hypothesis that ISBCS is non-inferior to DSBCS in terms of effectiveness and supe

154 E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, wit

155 to SXT for UFI treatment, but the drugs are non-inferior to each other for culture-confirmed enteric

156 +FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% c

157 EVG/COBI/FTC/TDF was non-inferior to EFV/FTC/TDF; 305/348 (87.6%) versus 296/

158 Tofacitinib monotherapy was not shown to be non-inferior to either combination.

159 emtricitabine and tenofovir alafenamide was non-inferior to emtricitabine and tenofovir disoproxil f

160 .8 min, 95% CI -97.2 to -24.4; p=0.0015) and non-inferior to entacapone (-26.2 min, -63.8 to 11.4; p=

161 he 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was su

162 INTERPRETATION: Rivaroxaban was non-inferior to fondaparinux for treatment of superficia

163 ondaparinux to assess whether rivaroxaban is non-inferior to fondaparinux in the prevention of thromb

164 Fusion, both iterations of partial IRS were non-inferior to full spraying.

165 HbA1c at 52 weeks, canagliflozin 100 mg was non-inferior to glimepiride (least-squares mean differen

166 This study confirmed that TwinrabTM is non-inferior to HRIG in terms of providing an unbroken w

167 LVA dual therapy was effective and non-inferior to HVA dual therapy as first-line treatment

168 luded that ICD insertion without testing was non-inferior to ICD with testing.

169 to moderate PTSD to one traumatic event was non-inferior to individual face-to-face CBT-TF and shoul

170 herapy, and that group hypnotherapy would be non-inferior to individual hypnotherapy for patients wit

171 Group hypnotherapy was therefore non-inferior to individual hypnotherapy.

172 feriority margin of -20% was set (CT-P13 was non-inferior to infliximab if the lower limit of the two

173 This study investigated whether CT-P13 is non-inferior to infliximab in patients with Crohn's dise

174 Initial treatment with rituximab is non-inferior to initial TNF inhibitor treatment in patie

175 IDegLira was non-inferior to insulin degludec (estimated treatment di

176 ool for optimizing insulin pump settings was non-inferior to intensive insulin titration provided by

177 d trial which found oral ciprofloxacin to be non-inferior to intravenous (IV) ceftriaxone in terms of

178 Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of effi

179 ablish whether perioperative eltrombopag was non-inferior to intravenous immunoglobulin.

180 stablished whether sublingual misoprostol is non-inferior to intravenous oxytocin for treatment of po

181 inetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associ

182 DP was non-inferior to IP with respect to the primary outcome,

183 Co-trimoxazole prophylaxis was non-inferior to IPTp with respect to infant mortality (r

184 At 26 weeks, the fIPV booster was non-inferior to IPV (group B vs group A) for serotype 1

185 oral delafloxacin fixed-dose monotherapy was non-inferior to IV vancomycin/aztreonam combination ther

186 OCT guidance was non-inferior to IVUS guidance (one-sided 97.5% lower CI

187 Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76

188 Omadacycline (315 [88%] of 360) was non-inferior to linezolid (297 [83%] of 360) for early c

189 post-treatment evaluation, omadacycline was non-inferior to linezolid in the mITT (303 [84%] of 360

190 ythmic drug treatment after cardioversion is non-inferior to long-term treatment.

191 th injectable-based 'Bangladesh' regimen was non-inferior to longer regimens, and promising interim r

192 diotherapy and moderate hypofractionation is non-inferior to longer schedules.

193 At week 48, darunavir was non-inferior to lopinavir for the primary outcome (142 [

194 than 9 weeks' gestation, both regimens were non-inferior to medication abortion effectiveness in cli

195 NmCV-5 responses in both age groups were non-inferior to MenACWY-TT responses for all five serogr

196 Ceftolozane-tazobactam was thus non-inferior to meropenem in terms of both 28-day all-ca

197 INTERPRETATION: Ceftazidime-avibactam was non-inferior to meropenem in the treatment of nosocomial

198 Solithromycin was non-inferior to moxifloxacin in achievement of early cli

199 ATB-346 was non-inferior to naproxen in terms of its inhibition of c

200 Gepotidacin was non-inferior to nitrofurantoin in both studies and super

201 95% CI 0.866-0.981) respectively, which were non-inferior to non-alcohol aetiologies.

202 In our primary analysis, OFA was non-inferior to OCR in terms of relapses, disability pro

203 OFA was non-inferior to OCR in the overall cohort.

204 Gaviscon(R) was non-inferior to omeprazole in achieving a 24-h heartburn

205 Once-weekly dulaglutide is non-inferior to once-daily liraglutide for least-squares

206 ence 0.061 L [0.037 to 0.086]; p<0.0001) and non-inferior to open triple (-0.003L [-0.033 to 0.027];

207 her a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabi

208 Oral solithromycin was non-inferior to oral moxifloxacin for treatment of patie

209 es with, or at risk for, ASCVD, ITCA 650 was non-inferior to placebo.

210 ancer, survival with primary chemotherapy is non-inferior to primary surgery.

211 We conclude that "Engage" is non-inferior to PST.

212 tion and dosing stability and was clinically non-inferior to PT monitoring.

213 It is hypothesized that bevacizumab is non-inferior to ranibizumab regarding its effectiveness.

214 However, if proved non-inferior to ranibizumab, use of the off-label bevaci

215 patients with diabetes, Cre8 EVO stents were non-inferior to Resolute Onyx stents with regard to targ

216 Fully oral RC8 regimen was non-inferior to RS8 for treatment of early, limited Buru

217 zero (p=0.59), showing that RC8 treatment is non-inferior to RS8 treatment for lesion healing at 52 w

218 S,S) vaccination showed that vaccination was non-inferior to seasonal malaria chemoprevention (SMC) i

219 contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 t

220 defined the reference standard, the DLS was non-inferior to six other dermatologists and superior to

221 r tyrosine-kinase inhibitor, was found to be non-inferior to sorafenib in terms of overall survival (

222 lpation as the only in-person component, was non-inferior to standard care with respect to rates of c

223 Combined treatment for SAM and MAM is non-inferior to standard care.

224 Although clinical response may be non-inferior to standard L-AmB therapy, a confirmatory p

225 ak evidence that low-intensity monitoring is non-inferior to standard monitoring in patients with a m

226 isits with ART dispensing every 6 months was non-inferior to standard of care and 3-monthly ART dispe

227 6-month PrEP dispensing was considered non-inferior to standard of care if the lower limit boun

228 Dabigatran was non-inferior to standard of care in terms of efficacy, w

229 Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a trea

230 ETATION: Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolon

231 h lopinavir and ritonavir plus lamivudine is non-inferior to standard triple therapy.

232 p, showing that aspiration as first pass was non-inferior to stent retriever first line (p(non-inferi

233 Oral semaglutide was non-inferior to subcutaneous liraglutide and superior to

234 Oral semaglutide was non-inferior to subcutaneous liraglutide in decreasing H

235 was met, demonstrating that TAXUS Liberte is non-inferior to TAXUS Express.

236 and peginterferon alfa-2a and ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and

237 e 1-infected previous non-responders and was non-inferior to telaprevir, thus providing an alternativ

238 ive HBV infection, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had i

239 G in ChAd/BNT recipients (12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/m

240 in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous ritux

241 bella plus LJEV group (478 [94%] of 507) was non-inferior to that in the measles-rubella group (473 [

242 bella plus LJEV group (496 [98%] of 507) was non-inferior to that in the measles-rubella group (499 [

243 -1)) within the AI-DSS arm was statistically non-inferior to that in the physician arm (1.3 +/- 1.4%

244 r the sensitivity of a single Ultra test was non-inferior to that of a single liquid culture for dete

245 be required to demonstrate efficacy that is non-inferior to that of a standard regimen of 6 months t

246 Treatment of latent yaws was taken to be non-inferior to that of active yaws if the lower limit o

247 oquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 o

248 nd ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients with a GMR

249 nd ChAd/NVX (5597 ELU/mL [4756 to 6586]) was non-inferior to that of ChAd/ChAd recipients with a GMR

250 nd potent antiretroviral activity, which was non-inferior to that of efavirenz at week 48.

251 rile children managed by the e-POCT tool was non-inferior to that of febrile children managed by a va

252 V, the efficacy of tenofovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, a

253 se of the jet injector group was regarded as non-inferior to that of the needle and syringe group if

254 eous closure of the LAA with this device was non-inferior to that of warfarin therapy.

255 overall survival on intermittent therapy was non-inferior to that on continuous therapy, with a prede

256 .077, 95% CI -0.83 to -0.53) was similar and non-inferior to that with biaspart insulin (-0.76%, 0.07

257 V screen, VIA triage and treat' strategy was non-inferior to the 'screen and treat' strategy as the l

258 DNA less than 29 IU/mL at week 48, which was non-inferior to the 195 (67%) of patients receiving teno

259 to determine whether the 6 + 10 schedule was non-inferior to the 6 + 14 schedule at 9 months of age,

260 image quality parameters were statistically non-inferior to the age- based protocol (p < 0.05).

261 The study regimen was non-inferior to the control for virological rebound cumu

262 the bictegravir regimen was achieved and was non-inferior to the dolutegravir regimen in previously u

263 esorbable polymer sirolimus-eluting stent is non-inferior to the durable polymer everolimus-eluting s

264 pregnancies of less than 9 weeks' gestation, non-inferior to the effectiveness of clinician-managed m

265 imus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer s

266 The Personalized Approach was non-inferior to the Household Approach in preventing SST

267 ty was 10.0 per 1000 person-years, which was non-inferior to the HSID cohort, incidence rate differen

268 ccine given with the jet injector device was non-inferior to the immune response to influenza vaccine

269 oradiologists the model-expert agreement was non-inferior to the inter-expert agreement, [Formula: se

270 every 4 weeks (-0.25 g/L, -1.79 to 1.29) was non-inferior to the mean change for patients who continu

271 en for severe malaria in African children is non-inferior to the more complex WHO-recommended regimen

272 SAM, FSMS-RUTF and MSMS-RUTF treatments were non-inferior to the PM-RUTF treatment in restoration of

273 bust antibody responses in children that was non-inferior to the responses induced in vaccinated adul

274 GPT-4 was non-inferior to the second human annotator in all datase

275 er 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regardin

276 WHO-prequalified yellow fever vaccines were non-inferior to the standard dose in inducing seroconver

277 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions ov

278 nths, the 6-monthly ART dispensing group was non-inferior to the standard of care group (percentage-p

279 The Supraflex stent was non-inferior to the Xience stent for a device-oriented c

280 chieve trough serum concentrations that were non-inferior to those achieved with intravenous rituxima

281 concentrations that were pharmacokinetically non-inferior to those achieved with intravenous rituxima

282 l(-1)))-in the AI-DSS arm were statistically non-inferior to those in the physician arm (50.2 +/- 11.

283 diethylcarbamazine plus albendazole, IDA) is non-inferior to three annual doses of ivermectin plus al

284 the same timepoint, two doses of PCV13 were non-inferior to three doses of PCV10 for nine of the ten

285 views is possible with high accuracy and is non-inferior to three radiographers.

286 were to investigate whether indacaterol was non-inferior to tiotropium for trough forced expiratory

287 of -0.055 L, suggesting that indacaterol was non-inferior to tiotropium.

288 Dual therapy was classed as non-inferior to triple therapy if the lower bound of the

289 l once-daily tedizolid 200 mg for 6 days was non-inferior to twice-daily linezolid 600 mg for 10 days

290 Once-daily oral omadacycline was non-inferior to twice-daily oral linezolid in adults wit

291 and multidose (551 [99.6%] of 553) EuTCV was non-inferior to Typbar TCV (198 [98.0%] of 202), with a

292 GP-ELISA titers were superior to placebo and non-inferior to vaccinated adults.

293 Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC.

294 Isavuconazole was non-inferior to voriconazole for the primary treatment o

295 e that ximelagatran has not been shown to be non-inferior to warfarin.

296 Latanoprost Polpharma was shown to be non-inferior to Xalatan((R)).

297 genous bone graft (ABG) may be a clinically "non-inferior" treatment modality as compared with the as

298 Assuming non-inferior vaccine characteristics for one dose compar

299 primary and secondary outcome variables were non-inferior with the following margins: CAL with a non-

300 s 11.2% (12 of 107) for sham control (judged non-inferior, with a posterior probability of 1.00 [Baye